ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
I read with interest the article about HEC Pharm, in particular where it says that HEC “has obtained regulatory approval to start clinical trials in China for morphothiadine mesilate, a treatment for hepatitis B virus that was discovered, and later dropped, by Bayer” (C&EN, Feb. 27, page 32).
I am a German chemist who worked for Bayer for 25 years. Now I am a consultant with HEC. I introduced this particular drug project to the company. It is not true that the drug was discovered and developed by Bayer and later dropped. Morphothiadine mesilate was synthesized in China. It is a new compound protected by new patents. At Bayer, this compound was never synthesized. The misunderstanding could be that the new concept to fight the hepatitis B virus using this approach is originally from Bayer. But the drug itself is not from Bayer.
By Siegfried Goldmann
Wuppertal, Germany
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter